OHE https://validator.w3.org/feed/docs/rss2.html Around the World in HTAs: Japan – An algorithmic approach to containing costs World EPA Congress 2027 OHE Annual Lecture 2026 | Paying for prevention: the global health financing challenge  OHE Can joint clinical assessment speed up access to medicines? One Europe, one assessment? Unpacking the European Joint Clinical Assessment Should HTA look beyond the healthcare system? What is your health worth? PROMs, EQ-5D & economic evaluation Cost-effectiveness thresholds: theory, pragmatism, and NICE’s new number Can HTA keep up with innovation? Net zero healthcare: Does HTA have a role to play? Most Favored Nation pricing: what it means for policy, patients and pharma  Addressing the systemic challenges of underinvestment in prevention Prevention works, so why don’t we pay for it? Around The World in HTAs: Spain – Are We There Yet? Around the World in HTAs: Spain – Closer than ever, but not quite yet The prevention paradox: we know it works, so why won’t we pay for it? Mid-year health check: policy, pricing & what’s coming José María Abellán-Perpiñán Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE Amanda Cole How long are patients WAITing for new treatments? Valuing Health at the End of Life: An Exploratory Preference Elicitation Study Comparing the UK EQ-5D-3L and the English EQ-5D-5L Value Sets Age and Utilities: Issues for HTA Public Preferences for Health Gains and Cures: A Discrete Choice Experiment Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ? Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead Our governance and network Nancy Devlin Does Government Funding Increase Public Sector Development of New Medicines? Koonal Shah NICE Recommendation Highlights Role of Social Value Judgements Alan Maynard – Alas No More The Long-term Sustainability of the NHS and Adult Social Care 5 Things You Should Do with EQ-5D Data Do child QALYs = adult QALYs? Five reasons why they might not 25 Years of the Cost Effectiveness Acceptability Curve NICE and EuroQol Research Foundation to Support New EQ-5D-5L Valuation Study The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19? International Women’s Day: Why We #Choosetochallenge How Should the World Pay for a COVID-19 Vaccine? The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’ A NICE Wind of Change? The What and So What of the NICE Methods Consultation Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments OHE at HESG Winter 2021 ‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum Efficiency Measurement in Primary Care: Time to Overcome the Challenges and Achieve Some Gains Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?